Unicycive Therapeutics (UNCY) EBITDA (2020 - 2026)

Unicycive Therapeutics (UNCY) has reported EBITDA for 7 consecutive years, with -$10.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 45.63% year-over-year to -$10.1 million; the trailing twelve-month figure through Jun 2026 stood at -$33.1 million (down 8.79% YoY), and the FY2025 full-year result was -$29.5 million, up 8.1% from the prior year.
• EBITDA declined to -$10.1 million in Q2 2026 per UNCY's latest filing, from -$8.4 million in the prior quarter.
• Across five years, EBITDA topped out at -$3.5 million in Q1 2022 and bottomed at -$10.1 million in Q2 2026.
• Historically, EBITDA has averaged -$6.6 million across 5 years, with a median of -$6.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA plunged 383.86% in 2022, then increased 22.0% in 2025.
• Over 5 years, EBITDA stood at -$5.3 million in 2022, then retreated by 18.55% to -$6.3 million in 2023, then tumbled by 46.7% to -$9.3 million in 2024, then grew by 22.0% to -$7.2 million in 2025, then sank by 40.37% to -$10.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$10.1 million, -$8.4 million, and -$7.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.